SCREENING MODELS OF ANTI-PARKINSONIAN AGENTS
AbstractParkinson’s disease (PD), identified as the second most common neurodegenerative disorder, is a progressive disease that impairs the ability to control voluntary movements mainly. According to the findings of the pathogenesis of PD, lesions in dopaminergic innervation of the basal ganglia cause degeneration of neurons in the substantia nigra and thus leads to loss of striatal dopamine level. Hence, enhancement of dopaminergic transmission restores partial motor functions. In the current review, the possible in-vivo animal models have been described in detail, which mostly resembles the Parkinsonian state in humans and has helped research involving pathogenesis, treatment, and evaluating drugs having Anti-Parkinson activity. This study aims to set down all the possible models to screen agents that have a therapeutic or symptomatic role in treating Parkinson’s disease. Every model has its advantage and disadvantage, which must be carefully considered when choosing the model to be used.
Article Information
3
2230-2241
1971 KB
1083
English
IJPSR
V. G. Kanase *, P. M. Pandagale and S. M. Dani
Department of Pharmacology, Oriental College of Pharmacy, Navi Mumbai, Maharashtra, India.
vanita.kanse@ocp.edu.in
28 August 2021
27 October 2021
12 November 2021
10.13040/IJPSR.0975-8232.13(6).2230-41
01 June 2022
Download